A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
300 patients around the world
Available in United States, Brazil, Belgium, Spain
Eli Lilly and Company
9Research sites
300Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 1
Requirements for the patient
To 35 Years
All Gender
Medical requirements
Have a new diagnosis of type 1 diabetes.
Have at least one diabetes-related autoantibody found at screening.
Show signs of remaining beta-cell function.
Stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening.
Random C-peptide result >0.3 nmol/L (0.9 ng/mL) during the screening period.
Weigh at least 8 kilograms (kg) (18 pounds) at screening.
Have any other type of diabetes including gestational.
Have uncontrolled high blood pressure.
Have had a heart attack, heart disease, stroke, or heart failure.
Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy.
Have a current or recent clinically serious medical condition or infection.
Sites
IPEC - Instituto de Pesquisa Clínica
Rua Marquês de Itú 503, Cj 31, São Paulo, Sao Paulo
Centro de Diabetes Curitiba - Curitiba, Parana
Rua Alcidez Munhoz, 433, 4º andar, sala 448, Curitiba, Parana
Hospital das Clínicas de Ribeirão Preto
Campus Universitário S/N, Bloco G Subsolo II, Monte Alegre, Ribeirão Preto, Sao Paulo
Universidade Federal do Rio de Janeiro - Faculdade de Medicina - UFRJ
Bloco K - Av. Carlos Chagas Filho, 373 - 2º andar, Sala 49 - Cidade Universitária da Universidade Federal do Rio de Janeiro, Rio de Janeiro - RJ, 21044-020
CPClin – Centro de Pesquisas Clinicas LTDA
Avenida Angélica, 2162 – Consolação – São Paulo, SP, CEP:01228-200